Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could stem cells ease your aching back?

NCT ID NCT04104412

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether stem cells from umbilical cords can safely relieve chronic low back pain caused by damaged spinal discs. It involves 242 adults with persistent pain for over 6 months. Participants receive stem cells injected into the disc, and researchers track pain levels and disability over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
human umbilical cord mesenchymal stem cells
What this could lead to
If it works, this could point toward a new way to treat chronic back pain without surgery or long-term painkillers.
What could go wrong
This is a very early Phase 1 trial, so it is mainly checking safety. The stem cells may not reduce pain, and there could be unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 242 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2019

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. age over 18 2. refractory and persistent lumbago pain for more than 6 months, with/without radiation pain in lower limbs, and poor conservative treatment effect; 3. the straight leg elevation test was 70 degrees negative; 4. MRI of lumbar spine showed herniated disc \< 6 mm, no obvious compression of spinal cord and nerve roots; T2-weighted mri of the lumbar spine showed decreased single/multi-segment signal (black disc sign) or High signal zone (HIZ) in the posterior part of the intervertebral disc annulus. 5. clinical signs of nerve localization were consistent with MRI changes; 6. subject gives informed consent and signs informed consent. Exclusion Criteria: 1. coagulation dysfunction or anticoagulant therapy; 2. intervertebral space infection, puncture site infection or systemic infection; 3. lumbago pain of non-spinal origin, such as sacroiliac joint origin pain; 4. patients who have had open surgery or other disc treatments; 5. imaging examination suggested disc prolapse, prolapse, spinal canal bone stenosis, etc.; 6. patients with vital organ system dysfunction and tumor lumbar vertebra metastasis; 7. subjects with high tumor markers (AFP/CEA/CA199/CA125); 8. the subject is pregnant or breastfeeding; 9. subjects also receive other treatments that may affect the efficacy and safety of stem cells; 10. failing to control alcohol and other substance abuse during the 6 months prior to enrollment and enrollment period; 11. the subjects suffer from mental illness, or lack of understanding, communication and cooperation, and cannot be guaranteed to follow the study protocol; Subjects who are not willing to sign informed consent and are participating in other clinical trials or have participated in other clinical trials within 3 months;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lumbar discogenic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xuanwu Hospital Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.